You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Overview

Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1 of SPC).1
Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.1

Reference:

  1. Volibris Summary of Product Characteristics (SPC). Available at http://www.medicines.ie/medicine/15338/SPC/Volibris+5+mg+and+10+mg+film-coated+tablets/. Last Accessed - April 2023.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Volibris is a registered trademark of Gilead, used under licence by the GlaxoSmithKline Group of Companies.